Impacts of Different Spirometry Reference Equations and Diagnostic Criteria on the Frequency of Airway Obstruction in Adult People of North China

References

• RoglianiP, OraJ, PuxedduE, CazzolaM. Airflow obstruction: is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:3007–3013. doi:10.2147/COPD27942210
   PubMed Web of Science ®Google Scholar
• HoggJC, McDonoughJE, SuzukiM. Small airway obstruction in COPD. Chest. 2013;143(5):1436–1443. doi:10.1378/chest.12-176623648907
   PubMed Web of Science ®Google Scholar
• CrapoRO. Pulmonary-function testing. N Engl J Med. 1994;331(1):25–30. doi:10.1056/NEJM1994070733101078202099
   PubMed Web of Science ®Google Scholar
• PellegrinoR. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/09031936.05.0003520516264058
   PubMed Web of Science ®Google Scholar
• Group SPFT. Guidelines for pulmonary function tests. Chin J Tubere Respir Dis. 2014(7). 487–491. doi: 10.3760/cma.j.issn.1001-0939.2014.07.002)
   Google Scholar
• GOLD. Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of COPD 2017. [ updated 2017; cited 2011]. Available from: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed 317, 2020.
   Google Scholar
• RenWY, ZhuL, ZhaoRY, et al. Preliminary study on medical reference range for adult pulmonary function parameters in Shanghai. Chin J Respir Crit Care Med. 2012;11(3):253–256.
   Google Scholar
• QuanjerPH, StanojevicS, ColeTJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. doi:10.1183/09031936.0008031222743675
   PubMed Web of Science ®Google Scholar
• LanghammerA, JohannessenA, HolmenTL, et al. Global lung function initiative 2012 reference equations for spirometry in the Norwegian population. Eur Respir J. 2016;48(6):1602–1611. doi:10.1183/13993003.00443-201627824594
   PubMed Web of Science ®Google Scholar
• HülsA, KrämerU, StolzS, et al. Applicability of the global lung initiative 2012 reference values for spirometry for longitudinal data of elderly women. PLoS One. 2016;11(6):e157569. doi:10.1371/journal.pone.0157569
   PubMed Web of Science ®Google Scholar
• AriglianiM, CancianiMC, MottiniG, et al. Evaluation of the global lung initiative 2012 reference values for spirometry in African children. Am J Resp Crit Care. 2017;195(2):229–236. doi:10.1164/rccm.201604-0693OC
   PubMed Web of Science ®Google Scholar
• SlatteryF, SchermerT, EstermanA, JohnstonK, CrockettA. The global lung function initiative 2012 equations are as well-suited as local population derived equations to a sample of healthy professional firefighters. Can Respir J. 2017;2017:1–6. doi:10.1155/2017/6327180
   Web of Science ®Google Scholar
• BackmanH, LindbergA, SovijärviA, LarssonK, LundbäckB, RönmarkE. Evaluation of the global lung function initiative 2012 reference values for spirometry in a Swedish population sample. BMC Pulm Med. 2015;15(1). doi:10.1186/s12890-015-0022-2
   PubMed Web of Science ®Google Scholar
• FasolaS, La GruttaS, CibellaF, CilluffoG, ViegiG. Global lung function initiative 2012 reference values for spirometry in South Italian children. Resp Med. 2017;131:11–17. doi:10.1016/j.rmed.2017.07.061
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.24141714
   PubMed Web of Science ®Google Scholar
• MillerMR. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• ShibuyaK, MathersCD, Boschi-PintoC, LopezAD, MurrayCJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 2002;2(1):37. doi:10.1186/1471-2407-2-3712502432
   PubMed Web of Science ®Google Scholar
• Linares-PerdomoO, HegewaldM, CollingridgeDS, et al. Comparison of NHANES III and ERS/GLI-2012 for airway obstruction classification and severity. Eur Respir J. 2016;48(1):133–141. doi:10.1183/13993003.01711-201527288032
   PubMed Web of Science ®Google Scholar
• SwanneyMP, RuppelG, EnrightPL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–1051. doi:10.1136/thx.2008.09848318786983
   PubMed Web of Science ®Google Scholar
• ViegiG, PedreschiM, PistelliF, et al. Prevalence of airways obstruction in a general population. Chest. 2000;117(5suppl 2):339S–345S.10843974
   PubMed Web of Science ®Google Scholar
• AndreevaE, PokhaznikovaM, LebedevA, MoiseevaI, KutznetsovaO, DegryseJ. The prevalence of chronic obstructive pulmonary disease by the global lung initiative equations in north-western Russia. Respiration. 2016;91(1):43–55. doi:10.1159/00044288726727503
   PubMed Web of Science ®Google Scholar
• Vaz FragosoCA, McAvayG, Van NessPH, et al. Phenotype of normal spirometry in an aging population. Am J Resp Crit Care. 2015;192(7):817–825. doi:10.1164/rccm.201503-0463OC
   PubMed Web of Science ®Google Scholar
• SiafakasNM, VermeireP, PrideNB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995;8(8):1398–1420. doi:10.1183/09031936.95.080813987489808
   PubMed Web of Science ®Google Scholar
• VogelmeierC, HedererB, GlaabT, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New Engl J Med. 2011;364(12):1093. doi:10.1056/NEJMoa100837821428765
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New Engl J Med. 2016;374(23):2222. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, BrookRD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• DecramerM, CelliB, KestenS, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–1178. doi:10.1016/S0140-6736(09)61298-819716598
   PubMed Web of Science ®Google Scholar
• TashkinDP, CelliB, SennS. A 4-year trial of tiotropium in chronic obstructive pulmonary disease — NEJM. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• HardieJA, BuistAS, VollmerWM, EllingsenI, BakkePS, MorkveO. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–1122. doi:10.1183/09031936.02.0002320212449163
   PubMed Web of Science ®Google Scholar
• MedbøA, MelbyeH. Lung function testing in the elderly—Can we still use FEV1/FVC<70% as a criterion of COPD? Resp Med. 2007;101(6):1097–1105.
   PubMed Web of Science ®Google Scholar
• TianXY, LiuCH, WangDX, et al. Spirometric reference equations for elderly Chinese in Jinan aged 60–84 years. Chin Med J (Engl). 2018;131(9):1016–1022. doi:10.4103/0366-6999.22784029553052
   PubMed Web of Science ®Google Scholar